Direct answer:QMSR entered into force on 2 February 2026 and the applicable manufacturer should use the existing 21 CFR Part 820, cited ISO 13485:2016 and other relevant FDA requirements. The ISO certificate already exists does not automatically represent full compliance with the FDA requirements; Procedures, actual implementation of records, supplementary provisions and current inspection arrangements should be checked simultaneously.

Quality systems, establishment registration, product listing and pre-market licensing have different roles to play. QMSR supports the need to clarify the scope of application, information and operational responsibilities of the enterprise and not to replace the system with an ordinary registered commodity or a certificate.

i. QMSR is in force and which enterprises are applicable?

QMSR took effect on 2026-02-02 and amended the medical device current good manufacturing practice requirements in 21 CFR Part 820. Applicability depends on the definition of a finished device manufacturer, actual activities and specific exemptions. A firm’s description of itself as a factory or trading company does not determine applicability.

Manufacturing activities as defined in the legislation include design, manufacture, assembly, processing, and also relate to the applicable contract elimination, relabelling, packaging or specifications development. The finished instruments do not require the completion of packaging, labelling or sterilisation to fall within this definition; Specific activities and product ranges should be verified on a case-by-case basis.

What is the relationship with ISO 13485 certificates?

QMSR incorporates its application requirements into FDA regulations by reference to ISO 13485:2016, while retaining the definition of FDA, additional provisions and other applicable legislation. ISO certification certificates can be used as information to understand the system, but cannot alone prove that all FDA requirements have been met and cannot substitute for FDA inspection or product listing permits.

A comparison should be established with the current version of the statute; ISO standards will be revised in the future, without automatically synchronizing changes to the quoted version of FDA. The title of the document cannot be changed from QSR to QMSR alone.

III. Which additional and related requirements need to be compared to the FDA?

  • Check specific requirements such as manufacturer definition, scope of application and design development according to current Part 820.
  • 820.35 Additional requirements for recording complaints, maintenance and application of UDI etc.
  • Check the label packing controls of 820.45, including applicable activities and records such as accuracy checks, use of release and prevention of confusion.
  • Other regulations, such as UDI, retroactive, MDR reporting and correcting removal, are linked as applicable.

These areas should incorporate corresponding procedures and responsibilities and should not be judged by a generic ISO checklist instead of specific FDA obligations. Exemptions to products and activities are also subject to verification of conditions on the basis of which full quality and post-market exemptions cannot be presumed.

IV. What information is needed before the gap assessment?

  • List of products, manufacturing and design activities, facilities and outsourcing relationships.
  • Existing quality manuals, procedures, catalogues of documents and segregation of duties.
  • Design, production, procurement of suppliers and risk-related information and implementation records.
  • Complaints, corrective measures, maintenance and procedures and records for the application of regulatory reports.
  • Labelling packaging, UDI, retroactive and change control information.
  • Management reviews, internal and vendor reviews, training, past inspections and modification of information.

Preliminary advice may be provided in the form of catalogues and summaries. Detailed records are provided in accordance with confidentiality, authorization and handover arrangements, and the products, sites, versions and scope of application are marked.

How can documentation, training and implementation be advanced?

A correspondence table of business activities with applicable requirements is established before comparing existing procedures and actual records and ranking gaps by risk and impact. Identify the responsible persons for the documents to be revised, the basis for support, the completion of the nodes and how the measures are validated.

Training and documentation should also be followed up by checking that actual performance records, such as vendor evaluation, tag release, complaint handling and change control are being implemented in accordance with procedures. Through internal review, management evaluation and proper impact verification, continuous tracking cannot be considered as the completion of the enterprise’s implementation of the consultant delivery document.

VI. What is the focus of the FDA inspection and historical records?

The FDA introduced an updated software manufacturer inspection program 7382.850 and discontinued the use of QSIT and associated old inspection files at 2026-02-02. Check preparation should be based on current requirements, rather than merely following the old QSR checklist.

FDA question-and-answer note, where investigators can review the records in the system, including those generated prior to entry into force; Exceptions to the established specific inspections for management reviews, quality reviews and vendor review reports were not retained. The enterprise should be able to access and account for the records and, if necessary, interpret the link between historical information and existing requirements by means of cross-referencing analysis, and maintain the original date of formation and the retroactive version.

VII. Service delivery, periodicity and common issues

Could the QMSR Advisory Council issue certificates for the FDA system?This item is system assessment, documentation and implementation collaboration and cannot be expressed as FDA authentication or assurance through inspection. Third-party certification and supervisory inspection are judged separately.

How long will it be done and how will the cost be determined?Gap analysis, document revision, training, practical implementation and review are assessed by facility, product and process scope. A breakdown of fees for services, third-party testing certification and applicable registration or declaration costs is provided, and there is no generic “FDA evidence-days”.

Do you want to maintain a registered listing after you finish the system?Needs to be extra-optimised. ConnectableGuidance on registration and listing、Label & DescriptionandUDI/GUDID, implementing separate data and quality procedures.

Official sources and service portals

View QMSR Gap Assessment and Implementation Support

Submission of summary information on enterprise activities and systems, scope of communication and quotations

Official data checks and updates: 2026-11-06. Author: Mr. Otsun; Audit: Mr. Toto. Application requirements should be verified in conjunction with specific equipment, entrepreneurial activities and existing legislation.

Continue reading and preparation

Further consolidation of project information is availableQMSR Quality System Compliance Support; The scope, processing cycles and costs are shown on the corresponding service page.